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Background: Although poor sleep is common in numerous gastrointestinal diseases, data are scarce on the risk
of poor sleep in celiac disease. The objective of this study was to estimate the risk of repeated use of hypnotics
among individuals with celiac disease as a proxy measure for poor sleep.
Methods: This is a nationwide case–control study including 2933 individuals with celiac disease and 14,571
matched controls from the general Swedish population. Poor sleep was defined as ≥2 prescriptions of hypnotics
using prospective data from the National Prescribed Drug Register (data capture: July 2005-January 2008). We
estimated odds ratios and hazard ratios for poor sleep before and after celiac disease diagnosis respectively.
Results: In this study, poor sleep was seen in 129/2933 individuals (4.4%) with celiac disease, as compared with
487/14,571 controls (3.3%) (odds ratio = 1.33; 95% CI = 1.08-1.62). Data restricted to sleep complaints starting ≥1
year before celiac disease diagnosis revealed largely unchanged risk estimates (odds ratio = 1.23; 95% CI = 0.88-1.71)
as compared with the overall risk (odds ratio 1.33). The risk of poor sleep in celiac disease was essentially not
influenced by adjustment for concomitant psychiatric comorbidity (n = 1744, adjusted odds ratio =1.26;
95% CI = 1.02-1.54) or restless legs syndrome (n = 108, adjusted odds ratio = 1.33; 95% CI = 1.08-1.63). Poor sleep
was also more common after celiac disease diagnosis as compared with matched controls (hazard ratio = 1.36;
95% CI = 1.30-1.41).
Conclusions: In conclusion, individuals with celiac disease suffer an increased risk of poor sleep, both before and after
diagnosis. Although we cannot rule out that surveillance bias has contributed to our findings, our results are consistent
with previous data suggesting that sleep complaints may be a manifestation of celiac disease.
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Celiac disease (CD) is a chronic autoimmune disorder
affecting 1-2% of the Western population [1]. In CD,
dietary gluten not only leads to small-intestinal villous
atrophy, but also affects organs outside the gastrointestinal
tract [2]. Individuals with CD therefore present with a great
variety of symptoms and signs: classical symptoms of
malabsorption (e.g. diarrhea with abdominal pain) and
non-classical symptoms (e.g. fatigue, peripheral neuropathy
and restless legs syndrome (RLS) [3]).* Correspondence: karlmarild@gmail.com
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unless otherwise stated.Poor sleep commonly includes difficulties in initiating
and maintaining sleep, or a non-restorative sleep with or
without daytime consequences [4]. According to Swedish
data, up to 20% of those with a self-reported sleeping
disorder use prescribed sleeping pills [5]. Although pre-
scription of hypnotics, such as benzodiazepines or
benzodiazepine-related drugs, is primarily recommended
for short-term treatment of acute sleep disorders, in
routine clinical practice pharmacological treatment is
also common for prolonged-periods (months to years)
of poor sleep [6].
Poor sleep frequently occurs in a number of gastro-
intestinal diseases, e.g. inflammatory bowel disease (IBD)
[7]. Not only may gastrointestinal symptoms impair the
quality of sleep, but poor sleep may also have a detrimentalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Overview methodology of main analysis: risk of poor
sleep before celiac disease diagnosis.
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gastrointestinal conditions [7]. Poor sleep may also add to
the burden of disease by reducing the quality of life [8] and
predispose to the development of comorbidities, such as
psychiatric diseases [9]. Although poor sleep has been
closely studied in many other gastrointestinal diseases [10],
to our knowledge, only one previous study has addressed
the risk of poor sleep in CD [11]. That cross-sectional
study, based on 60 patients identified at one tertiary center,
found poorer sleep quality among individuals with CD,
both before and after treatment with a gluten-free diet, as
compared with healthy volunteers [11].
In the current nationwide study including some 2900
individuals with CD we examined the risk of poor sleep
defined as repeated use of hypnotics, both before and
after CD diagnosis.
Methods
Data on individuals with CD were linked to the Swedish
Prescribed Drug Register [12] in order to examine the
risk of poor sleep in CD. Poor sleep was defined as re-
peated use (≥2 prescriptions) of hypnotics.
Study population
Between 2006 and 2008, we searched the computerized
register from all Sweden’s pathology departments (n =
28) to identify individuals with biopsy-verified CD, de-
fined as small-intestinal villous atrophy (Marsh grade 3)
[13]. We have earlier shown that 95% of Swedish indi-
viduals with villous atrophy have CD [13]. The current
study was based on the same dataset as described in our
study on mortality in CD, [14] originally including
29,096 individuals with CD diagnosed between 1969 and
2008. Time of CD diagnosis was defined as time of first
biopsy showing villous atrophy. For each of these
individuals with CD the government agency Statistics
Sweden tried to identify five controls matched for age,
sex, calendar period of birth and county of residence
through the Total Population Register, which includes
demographic data on all Swedish residents [15]. Controls
were sampled from all Swedish residents in whom the
computerized pathology registers did not indicate prior
duodenal/jejunal biopsy. After exclusion of controls with
data irregularities and those that could not be matched
144,522 controls were identified. Due to lack of eligible
controls some individuals with celiac disease only had
four controls and the average numb of controls per indi-
vidual with celiac disease was slightly below 5. Where a
patient had celiac disease, especially if diagnosed in old
age, the responsible government agency sometimes failed
to identify 5 matching controls. E.g. 76-year old man di-
agnosed with celiac disease in 1989 in Dalsland county.
This means that this person was born in 1913. It may
then have been that in 1989 there were only 4 othermales aged 76 year in the part of Dalsland where this
man lived.
We then linked data on individuals with CD and their
matched controls to the Prescribed Drug Register [12]
(established July 2005) in order to identify individuals
with repeated use of hypnotics before CD diagnosis (and
corresponding date in controls). Our main analysis was
therefore restricted to individuals diagnosed with CD be-
tween July 2005 and January 2008, including 2,933 indi-
viduals with CD and 14,571 matched controls. In order
to estimate the risk of poor sleep after CD diagnosis, we
performed a pre-planned subanalysis including 26,587
individuals with CD diagnosed between 1969 and 2008
and 133,465 matched controls with a follow-up until July
2005 (start of the Prescribed Drug Register) and with no
use of hypnotics prior to CD diagnosis. See Figures 1
and 2 for overview of study methodology.Poor sleep
The Prescribed Drug Register, established in July 2005,
contains prospectively recorded high-quality data on vir-
tually all prescribed drugs in Sweden [12]. In Sweden,
the use of hypnotics is strictly controlled and sleep med-
ications are generally not sold over the counter.
We collected data on use of hypnotics from July 1st
2005 through January 29th 2008 and up to the date of
CD diagnosis (and the corresponding date in matched
controls). In order to minimize the risk of false positive
cases we restricted our definition of poor sleep as ≥2
prescriptions of hypnotics before CD diagnosis. Hyp-
notics were classified according to the Anatomical
Therapeutic Chemical (ATC) pharmaceutical classifica-
tion system [16]: benzodiazepine-related drugs (i.e. non-
benzodiazepine GABA-A receptor agonists), benzodiaze-
pines, other hypnotics and melatonin receptor agonists
(see Additional file 1). A similar classification of hyp-
notics has previously been used [17]. Regrettably, the
National Patient Register is unsuitable for identification
of poor sleep (e.g. diagnosed insomnia) as this registry is
limited to International Classification of Disease (ICD)
codes from inpatient and non-primary outpatient care
clinics with low sensitivity to ascertain poor sleep.
Celiac disease 
(n=26,587) 
Matched controls 
(n=133,465)  
Prescribed Drug Register 
July 2005 - January 2008 
Repeated use of hypnotics 
Time: 1969-January 2008 
Figure 2 Overview methodology of subanalysis: risk of poor
sleep after celiac disease diagnosis.
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To investigate potential contributing factors to poor
sleep in individuals with CD we performed a post-hoc
analysis adjusting for sleep apnea and RLS since these
two conditions may impair sleep [18-20]. Most studies
have indicated an increased risk of RLS in CD [3,21],
possibly due to prevalent iron deficiency in celiac pa-
tients. There are no data on the specific risk of sleep
apnea in individuals with CD. We identified RLS using
relevant ICD-codes in the National Patient Register
(ICD-8: 787.00; ICD-9: 333X and ICD-10: G25.8) or as
prescription of dopaminergic drugs typically used in the
treatment of RLS (excluding individuals with concomi-
tant Parkinson’s disease) (see Additional file 2 for ATC-
codes). Sleep apnea was identified using the National
Patient Register (ICD-10: G47.3).Statistical analyses
We used conditional logistic regression to estimate Odds
Ratios (ORs) and 95% confidence intervals (CIs). Through
conditional logistic regression each stratum (one individ-
ual with CD compared with his/her matched controls)
was analyzed separately before a summary OR was calcu-
lated [22]. This statistical approach eliminated the effect of
sex, age, county and calendar year on our ORs. Practically,
conditional logistic regression works similar as regular
logistic regression except its comparison is carried out
in matched sets.
We performed stratified analyses by age at CD diagno-
sis (<19 years, 19–39 years, 40–59 years and ≥60 years)
and sex. The therapeutic indications differ between types
of hypnotics. In pre-planned subanalyses we therefore
estimated the association between CD and poor sleep
according to the type of hypnotics used: benzodiazepine-
related drugs, benzodiazepines, other hypnotics and mela-
tonin receptor agonists. We also estimated the dose- and
time-dependent association between use of hypnotics and
subsequent CD: (1) when individuals had received two or
at least three prescriptions of hypnotics and (2) when hyp-
notics had been prescribed in the last year (≤365 days) or
more than one year (>365 days) before CD diagnosis,
respectively.We considered education level [4,23], as a measure
of socioeconomic position, psychiatric comorbidity [24]
and epilepsy [25] as potential confounders. In a subana-
lysis we therefore adjusted for education level using
seven predefined education categories determined by
Statistics Sweden. We also adjusted for epilepsy and
psychiatric comorbidity, including substance use and
mood disorders, using relevant ICD-codes recorded in
the National Patient Register [26] (see Additional file 3
for ICD-codes).
Subanalyses
We used Cox regression to estimate Hazard Ratios
(HRs) and 95% CIs for poor sleep (≥2 prescriptions of
hypnotics) after CD diagnosis. In this subanalysis we in-
cluded 26,587 individuals with CD diagnosed between
1969 and 2008 and 133,465 matched controls with a
follow-up until July 2005 (start of the Prescribed Drug
Register) and with no use of hypnotics prior to CD diag-
nosis (see Figure 2 for overview of methodology of suba-
nalysis). Follow-up started at time of CD diagnosis (and
corresponding date in controls) and ended at time of
first prescription of hypnotics (July 2005 or later), death,
emigration or on December 31st 2009, whichever oc-
curred first. In controls, follow-up could also end if the
individual was diagnosed with CD. We performed strati-
fied analyses by sex and age at CD diagnosis as well as
subanalyses adjusting for education level, psychiatric co-
morbidity and epilepsy.
SPSS version 20.0 was used for all statistical analyses.
Ethics
This study was conducted in accordance with the na-
tional and institutional standards and was approved by
the Regional Ethical Vetting Board in Stockholm. Since
none of the participants was contacted and individual in-
formation was anonymized prior to the analyses, in-
formed consent was not required by the research ethics
committee.
Results
Some 40% of the individuals with CD had been diag-
nosed in childhood and 19% were aged 60 years or more
at time of diagnosis (median age at CD diagnosis was 28
years). Most of the individuals with CD included in our
main analysis were diagnosed in year 2006 and some
60% of the study participants were female (Table 1).
Overall, 129 individuals (4.4%) with CD had been
treated for poor sleep, as compared with 487 matched
controls (3.3%), corresponding to an OR of 1.33 (95%
CI = 1.08-1.62) (adjustment for education level: adjusted
OR = 1.34; 95% CI = 1.09-1.64). Because specific hyp-
notics may occasionally also be used in the treatment of
epilepsy and various psychiatric diseases we adjusted for
Table 1 Descriptive characteristics of individuals with
celiac disease (CD) and matched controls
Celiac disease Controls
Total 2933 14,571
Sex
Females (%) 1796 (61.2) 8926 (61.3)
Males (%) 1137 (38.8) 5645 (38.7)
Age at study entry,
years (median; rangea)
28; 0-94 28; 0-94
Age groups
≤19 years (%) 1218 (41.5) 6074 (41.7)
20-39 years (%) 566 (19.3) 2809 (19.3)
40-59 years (%) 583 (19.9) 2905 (19.9)
≥60 years (%) 566 (19.3) 2783 (19.1)
Calendar year of CD diagnosis
2005b (%) 819 (27.9) 4062 (27.9)
2006 (%) 1828 (62.3) 9097 (62.4)
2007c (%) 274 (9.3) 1352 (9.3)
2008d (%) 12 (0.4) 60 (0.4)
aTen children were diagnosed of CD during their first year of life and are in
the table referred to as age “0”.
bBeginning of study period: July 1st 2005.
cMost pathology departments only delivered small-intestinal biopsy data up to
the beginning of 2007. Therefore this study includes fewer individuals with CD
diagnosed 2007–2008, as compared with 2005–2006.
dEnd of study period: January 29th 2008.
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in risk estimates (epilepsy: n = 207; psychiatric disease:
n = 1744; adjusted OR = 1.26; 95% CI = 1.02-1.54).
The prevalence of poor sleep treated with prescribed
hypnotics increased with increasing age at CD diagnosis
being most common in those aged 60 years or older;
and there were very few children treated for poor sleep
(Table 2). Poor sleep was significantly associated with
CD in individuals aged ≥60 years at time of diagnosis
(OR = 1.40; 95% CI = 1.07-1.83); however the risk esti-
mates did not attain statistical significance in the youn-
ger age groups and with overlapping CIs between age
groups. Overall, poor sleep was more prevalent in fe-
males than in males (Table 2). However, there were only
small differences in risk estimates for poor sleep between
females (OR = 1.38; 95% CI = 1.08-1.76) and males with
CD (OR = 1.21; 95% CI = 0.83-1.75) as compared with
sex-matched controls.
Benzodiazepine-related drugs (e.g. Zolpidem) were the
most frequently used type of hypnotics, being used by
3.8% of individuals with CD and 2.6% of controls, corre-
sponding to an OR of 1.47 (95% CI = 1.18-1.82). There
were no significant associations between CD and use of
any of the remaining types of hypnotics (Table 2). We
found no indication of a dose–response relationship,
with similar risk estimates among individuals with atleast two prescriptions of hypnotics, as among those
with three or more prescriptions of hypnotics (Table 2).
To estimate a possible time-dependent association be-
tween poor sleep and subsequent CD we performed two
subanalyses estimating the association between poor
sleep present in the last year (≤365 days) and poor sleep
present more than one year (≥366 days) before CD diag-
nosis. Some 4.3% of individuals with CD, as compared
with some 3.2% in controls, suffered from poor sleep in
the year before CD diagnosis (OR = 1.35; 95% CI = 1.10-
1.65). The OR remained largely unchanged when we re-
stricted our data to poor sleep present more than one
year before CD diagnosis (OR = 1.23; 95% CI = 0.88-
1.71). In Tables 3 and 4 we describe the association be-
tween CD and poor sleep according to used hypnotics
subgroup and according to time to CD diagnosis.
In a number of pre-planned subanalyses we estimated
the risk of poor sleep after CD diagnosis (and corre-
sponding date in controls). During follow-up, 3323 of
26,587 individuals (12.5%) were treated for poor sleep
after CD diagnosis, as compared with 13,067/133,465
(9.8%) among controls, corresponding to a HR of 1.36
(95% CI = 1.30-1.41). The increased risk of poor sleep
after CD diagnosis remained largely unchanged when
adjusted for education level, epilepsy or psychiatric co-
morbidity (adjusted HR = 1.30; 95% CI = 1.25-1.36). Fur-
thermore, individuals with CD had a similar increased
risk poor sleep in the future irrespective of age at CD
diagnosis, sex and according to type of hypnotic used
(Table 5).
Post-hoc analyses
To investigate definitive sleep disorders among individ-
uals with CD and poor sleep we identified those with a
previous diagnosis of sleep apnea or with RLS (defined
by relevant ICD-code or prescription of drugs typically
used in RLS). In 19/2933 individuals with CD (0.6%) a
diagnosis of RLS was present, as compared with 89/
14,571 (0.6%) in controls. Sleep apnea was identified in
10/2933 (0.3%) of individuals with CD and in 63/14571
(0.4%) of controls. Adjustment for sleep apnea and RLS
did not influence the risk of poor sleep in CD (adjusted
OR = 1.33; 95% CI = 1.08-1.63).
Discussion
In this nationwide case–control study we found a mod-
estly increased risk of poor sleep (≥2 prescriptions of
hypnotics) in individuals with CD, both before and after
diagnosis. This association was not influenced by adjust-
ment for education, psychiatric disease, sleep apnea or
RLS. Although, we cannot rule out that surveillance bias
might have influenced our results, i.e. that individuals
with poor sleep also had other complaints resulting in a
CD investigation, the consistency of our results with
Table 2 Risk of poor sleep before celiac disease diagnosis
Celiac disease (%) Controls (%) Odds ratio 95% CI
Poor sleepa 128/2933 (4.4) 487/14,571 (3.3) 1.33 1.08-1.62
Type of hypnotics usedb
Benzodiazepine-related drugs 111 (3.8) 380 (2.6) 1.47 1.18-1.82
Benzodiazepines 17 (0.6) 65 (0.4) 1.28 0.76-2.16
Other hypnotics 32 (1.1) 143 (1.0) 1.11 0.76-1.62
Melatonin receptor agonistsc 0 (0.0) 2 (0.0) - -
≥3 prescriptions of hypnoticsc
Any hypnotics 78 (2.7) 359 (2.5) 1.07 0.84-1.38
Benzodiazepine-related drugs 62 (2.1) 256 (1.8) 1.19 0.90-1.58
Benzodiazepines 7 (0.2) 41 (0.3) 0.85 0.39-1.88
Other hypnotics 12 (0.4) 86 (0.6) 0.70 0.39-1.28
Melatonin receptor agonistsd 0 (0.0) 2 (0.0) - -
Age
≤19 years 1/1218 (0.1) 4/6074 (0.1) 1.23 0.15-9.80
20-39 years 8/566 (1.4) 49/2809 (1.7) 0.82 0.39-1.72
40-59 years 39/583 (6.7) 142/2905 (4.9) 1.38 0.96-1.97
≥60 years 80/566 (14.1) 292/2783 (10.5) 1.40 1.07-1.83
Sex
Males 36/1137 (3.2) 150/5645 (2.7) 1.21 0.83-1.75
Females 92/1796 (5.1) 337/8926 (3.8) 1.38 1.08-1.76
Odds ratios estimated through conditional logistic regression modelling.
aPoor sleep defined as ≥2 prescriptions of hypnotics before celiac disease diagnosis. Data capture of hypnotics: July 1st 2005-January 29th 2008.
bSee Additional file 1: Table S1 for anatomical therapeutic chemical (ATC) codes used to classify hypnotics.
cThe category “≥3 prescriptions of hypnotics” is being compared with the category “<3 prescriptions of hypnotics”.
dDue to lack of events no odds ratio was estimated.
Mårild et al. BMC Gastroenterology  (2015) 15:10 Page 5 of 8previous data [11] suggests that sleep complaints may be
a manifestation of CD.Strengths and weaknesses
A strength of our study is the use of prospectively recorded
exposure and outcome data, eliminating the risk of recall
bias. Further, the large statistical power allowed for import-
ant subanalyses, such as examination of dose- and time-
dependent associations. We were also able to adjust for sev-
eral potential confounders, e.g. psychiatric comorbidities.Table 3 Risk of poor sleep starting within 1 year before celiac
Celiac disease n = 2,933 (%)
Poor sleepa 126 (4.3)
Type of hypnotics usedb
Benzodiazepine-related drugs 84 (2.9)
Benzodiazepines 5 (0.2)
Other hypnotics 7 (0.2)
Melatonin receptor agonistsc 0 (0.0)
Odds ratios estimated through conditional logistic regression modelling.
aPoor sleep defined as ≥2 prescriptions of hypnotics before celiac disease diagnosis
bSee Additional file 1: Table S1 for anatomical therapeutic chemical (ATC) codes use
cDue to lack of events no odds ratio was estimated.The use of biopsy data to identify CD brings several ad-
vantages, such as being able to identify an average CD
population. The use of biopsy data also minimizes the risk
of CD misclassification. In Sweden, small intestinal biopsy
has long been the gold standard for diagnosing CD and
previous data have shown that more than 95% of Swedish
physicians perform a small-intestinal biopsy before diagnos-
ing CD [13]. An earlier validation study found that 95% of
Swedish individuals with villous atrophy have CD [13].
This study has some limitations. Although it is likely
that most of the individuals with repeated use of hypnoticsdisease diagnosis
Controls n = 14,571 (%) Odds ratio 95% CI
471 (3.2) 1.35 1.10-1.65
281 (1.9) 1.48 1.16-1.90
35 (0.2) 0.71 0.28-1.79
56 (0.4) 0.63 0.29-1.37
1 (0.0) - -
. Data capture of hypnotics: July 1st 2005-January 29th 2008.
d to classify hypnotics.
Table 4 Risk of poor sleep starting more than 1 year before celiac disease diagnosis
Celiac disease n = 1086 (%) Controls n = 5382 (%) Odds ratio 95% CI
Poor sleepa 49 (4.5) 200 (3.7) 1.23 0.88-1.71
Type of hypnotics usedb
Benzodiazepine-related drugs 40 (3.7) 151 (2.8) 1.32 0.92-1.90
Benzodiazepines 7 (0.6) 20 (0.4) 1.70 0.73-3.81
Other hypnotics 5 (0.5) 51 (0.9) 0.49 0.20-1.23
Melatonin receptor agonistsc - - - -
aPoor sleep defined as ≥2 prescriptions of hypnotics before celiac disease diagnosis. Data capture of hypnotics: July 1st 2006-January 29th 2008.
bSee Additional file 1: Table S1 for anatomical therapeutic chemical (ATC) codes used to classify hypnotics.
cDue to lack of events no odds ratio was estimated.
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ficulty initiating sleep, disrupted sleep and non-restorative
sleep, we lack data on the specific nature of these com-
plaints. Furthermore, previous data have shown that rela-
tively few of those with a self-reported sleeping disorder
receive treatment with hypnotics [5]. Although the patho-
genesis may be similar in mild and more severe sleep com-
plaints, our results may primarily represent severe sleep
complaints requiring hypnotic prescription. Traditionally,
prescription of hypnotics in children with poor sleep has
been limited, and with the short follow-up of children in
this study we may have underestimated the prevalence of
poor sleep in children.
To minimize the risk of false positive cases we re-
stricted our definition of poor sleep to repeated (≥2) pre-
scriptions of drugs that are mainly indicated for the
treatment of poor sleep. We acknowledge that some of
the study participants with sleep complaints may have
been prescribed treatments that were not included inTable 5 Risk of poor sleep after celiac disease diagnosis
Celiac disease n = 26,587 (%)
Poor sleepa 3323 (12.5)
Age at CD diagnosis
≤19 years 298/11,708 (2.5)
20-39 years 608/5170 (11.8)
40-59 years 1223/5960 (20.5)
≥60 years 1194/3749 (31.8)
Sex
Males 957/9815 (9.8)
Females 2366/16,772 (14.1)
Type of hypnotics usedb
Benzodiazepine-related drugs 2782/26,591 (10.5)
Benzodiazepines 394/26,610 (1.5)
Other hypnotics 1191/26,604 (4.5)
Melatonin receptor agonists 148/26,611 (0.6)
Hazard ratios estimated through cox regression modelling.
aPoor sleep defined as ≥2 prescriptions of hypnotics after CD diagnosis. Data captu
bSee Additional file 1: Table S1 for anatomical therapeutic chemical (ATC) codes useour definition of hypnotics, e.g. sedating antidepressants.
Furthermore, non-adherence to prescribed hypnotics as
well as the left truncation of exposure data with no data
on hypnotic use before July 2005, may also cause mis-
classification of our definition of poor sleep. However,
such potential misclassification should not differ by CD
status and therefore not lead to spurious associations,
but might instead somewhat underestimate the true
effect.
Previous studies
We know of only one previous study on the risk of poor
sleep in CD. In 2010, Zingone et al. [11] used the Pittsburg
Sleep Quality Index and found that compared with
healthy volunteers, both untreated and treated celiac
patients had significantly poorer sleep quality, including
prolonged sleep latency and shorter duration of sleep.
In this study, including 60 patients from a tertiary centre,
sleep quality was inversely associated with both mentalControls n = 133,465 (%) Hazard ratio 95% CI
13,067 (9.8) 1.36 1.30-1.41
1058/57,940 (1.8) 1.41 1.24-1.61
2003/25,672 (7.8) 1.54 1.41-1.69
4659/30,252 (15.4) 1.37 1.29-1.47
5347/19,601 (27.3) 1.24 1.16-1.33
3920/49,688 (7.9) 1.32 1.22-1.42
9147/83,777 (10.9) 1.37 1.31-1.44
10898/133,492 (8.2) 1.35 1.30-1.41
1334/133,547 (1.0) 1.59 1.41-1.78
4847/133,536 (3.6) 1.28 1.20-1.37
445/133,557 (0.3) 1.69 1.40-2.04
re of hypnotics: July 1st 2005-January 29th 2008.
d to classify hypnotics.
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sity of gastrointestinal symptoms. Our results are consist-
ent with the results of Zingone et al., although the studies
differ by study design.
Poor sleep has been recognized as a manifestation of
several gastrointestinal conditions [10,27] including ac-
tive as well as inactive IBD [7]. Conversely, poor sleep
may have a detrimental effect on the course of both
functional [28] and inflammatory gastrointestinal condi-
tions, and several studies on IBD have found that sleep
impairment may increase the risk of disease flares
[29,30]. However, even though poor sleep has been
shown to influence ubiquitous pro-inflammatory media-
tors [31] there is no plausible biological explanation for
a causal association between poor sleep and develop-
ment of CD. A non-causal association between CD and
poor sleep is further supported by the lack of a dose-
and time-dependent association in this study.
Interpretation of findings
We found an increased risk of poor sleep both before
and after CD diagnosis that was not explained by psychi-
atric comorbidity, sleep apnea or RLS. Our results are
consistent with previous data on CD and other gastro-
intestinal diseases suggesting that poor sleep may be a
manifestation of CD. Individuals with CD suffer from
numerous symptoms that may impair the quality of
sleep [2]. Furthermore, even though most CD manifesta-
tions typically resolve on a gluten-free diet, some symp-
toms may persist, in particularly when dietary adherence
is poor [32]. Regrettably, we lack dietary data in this
study. However, in an earlier validation study off a ran-
dom sample of individuals with villous atrophy, 15/86
(17%) had poor dietary adherence [13].
Finally, we cannot rule out that the association seen in
this study was influenced by surveillance bias with an in-
creased detection of CD in individuals with poor sleep.
It is well known that individuals with poor sleep have an
increased health care consumption [33], including in-
creased drug use [9]. In addition, studies have shown a
mean diagnostic delay of more than five years from on-
set of CD symptoms to diagnosis [34], a time associated
with an increased number of outpatients visits [35] and
possibly an increased likelihood of receiving treatment
for poor sleep. Regrettably, we lack data on clinical char-
acteristics of those individuals with CD. However, the
lack of a time-dependent association between poor sleep
and CD diagnosis, argues against surveillance bias as the
sole cause of our findings.
Conclusions
In conclusion, individuals with CD suffer an increased
risk of poor sleep, measured as repeated use of pre-
scribed hypnotics, both before and after diagnosis. Theexcess risk was not influenced by psychiatric comorbidi-
ties. Although, we cannot rule out that surveillance bias
has contributed to our findings, our results are consist-
ent with earlier research suggesting that poor sleep may
be a manifestation of CD.
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